RxDoctor Payments Data

Paul Pandolfi, MD

Family Medicine · Navarre, FLNPI 1982660023

Payments from drug & device makers

$345in general payments, 2019–2025

Across 19 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$197
  • AbbVie$44
  • Biohaven Pharmaceutical Holding Company Ltd.$38
  • Takeda Pharmaceuticals U.S.A., Inc.$38
  • Idorsia Pharmaceuticals US Inc$14
  • Sanofi-aventis U.S. LLC$14

What the payments were for

  • Food & beverage$345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$345 in reported general payments places this provider in the 40th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$159,879
Medicare patients
270
Services billed
2,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$130,685
EliquisApixaban104$100,157
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$66,921
JardianceEmpagliflozin39$53,029
MyrbetriqMirabegron51$41,844
XareltoRivaroxaban33$28,636
FarxigaDapagliflozin Propanediol23$25,862
MounjaroTirzepatide16$23,662
Tresiba Flextouch U-100Insulin Degludec28$23,138
LinzessLinaclotide31$21,961
JanuviaSitagliptin Phosphate17$21,300
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$15,791
Breo ElliptaFluticasone/Vilanterol23$13,096
EntrestoSacubitril/Valsartan12$13,032
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen400$11,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$197$80,01798 claims
AbbVieLinzess, Savella$44$27,67243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Navarre

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →